Wordt geladen...
A Randomized, Double‐Blind, Placebo‐ and Positive‐Controlled, 4‐Period Crossover Study of the Effects of Solriamfetol on QTcF Intervals in Healthy Participants
Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, is approved (United States and European Union; Sunosi) to treat excessive daytime sleepiness associated with narcolepsy (75‐150 mg/day) or obstructive sleep apnea (37.5‐150 mg/day). A thorough QT/QTc study assessed solriamfetol effects...
Bewaard in:
| Gepubliceerd in: | Clin Pharmacol Drug Dev |
|---|---|
| Hoofdauteurs: | , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
John Wiley and Sons Inc.
2020
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8048583/ https://ncbi.nlm.nih.gov/pubmed/32935460 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpdd.867 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|